HONG KONG – Singapore startup Enleofen Bio Pte Ltd. has acquired the licensing rights of a breakthrough discovery by the Duke-National University of Singapore (NUS) Medical School and the National Heart Centre Singapore (NHCS) in cardiovascular fibrosis drivers.